Mesenchymal stem cells in tuberculosis therapy
- Authors: Remezova A.N.1, Gorelova A.A.1,2, Muraviev A.N.2,3, Vinogradova T.I.2, Gorelov A.I.1,4, Gorbunov A.I.2, Orlova N.V.2, Yudintseva N.M.5, Nashchekina Y.A.5, Sheykhov M.G.2, Yablonsky P.K.1,2
-
Affiliations:
- Saint Petersburg State University
- Saint Petersburg Research Institute of Phtisiopulmonology
- Saint Petersburg Medico-Social Institute
- Pokrovskaya Municipal Hospital
- Institute of Cytology
- Issue: Vol 23, No 9 (2021)
- Pages: 462-465
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95512
- DOI: https://doi.org/10.26442/20751753.2021.9.200953
- ID: 95512
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Anna N. Remezova
Saint Petersburg State Universityординатор каф. Saint Petersburg, Russia
Anna A. Gorelova
Saint Petersburg State University; Saint Petersburg Research Institute of Phtisiopulmonology
Email: gorelova_a@yahoo.com
мл. науч. сотр. Saint Petersburg, Russia
Alexander N. Muraviev
Saint Petersburg Research Institute of Phtisiopulmonology; Saint Petersburg Medico-Social Instituteканд. мед. наук, ученый секретарь Saint Petersburg, Russia
Tatjana I. Vinogradova
Saint Petersburg Research Institute of Phtisiopulmonologyд-р мед. наук, проф., гл. науч. сотр. Saint Petersburg, Russia
Andrey I. Gorelov
Saint Petersburg State University; Pokrovskaya Municipal Hospitalд-р мед. наук, проф., зав. отд-нием Saint Petersburg, Russia
Alexander I. Gorbunov
Saint Petersburg Research Institute of Phtisiopulmonologyмл. науч. сотр. Saint Petersburg, Russia
Nadezhda V. Orlova
Saint Petersburg Research Institute of Phtisiopulmonologyнауч. сотр. Saint Petersburg, Russia
Natalya M. Yudintseva
Institute of Cytologyканд. биол. наук, ст. науч. сотр. Saint Petersburg, Russia
Yulia A. Nashchekina
Institute of Cytologyканд. биол. наук, науч. сотр. Saint Petersburg, Russia
Magomedsadyk G. Sheykhov
Saint Petersburg Research Institute of Phtisiopulmonologyаспирант Saint Petersburg, Russia
Petr K. Yablonsky
Saint Petersburg State University; Saint Petersburg Research Institute of Phtisiopulmonologyд-р мед. наук, проф., дир. Saint Petersburg, Russia
References
- Васильева И.А., Белиловский Е.М., Борисов С.Е., Стерликов С.А. Туберкулез с множественной лекарственной устойчивостью возбудителя в странах мира и в Российской Федерации. Туберкулез и болезни легких. 2017;95(11):5-17
- Global Tuberculosis Report 2018. WHO/CDS/TB/2018.20. Geneva, World Health Organization, 2018; p. 95-6.
- Иванова Д.А., Борисов С.Е., Родина О.В., и др. Безопасность режимов лечения больных туберкулезом с множественной лекарственной устойчивостью возбудителя согласно новым рекомендациям ВОЗ 2019 г. Туберкулез и болезни легких. 2020;98(1):5-15
- Бурмистрова И.А., Самойлова А.Г., Тюлькова Т.Е., и др. Лекарственная устойчивость M. tuberculosis (исторические аспекты, современный уровень знаний). Туберкулез и болезни легких. 2020;98(1):54-61
- Кульчавеня Е.В. Служба внелегочного туберкулеза в Сибири и на Дальнем Востоке. Туберкулез и болезни легких. 2019;97(1):7-11
- Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-32.
- Mbuagbaw L, Guglielmetti L, Hewison C, et al. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg Infect Dis. 2019;25(5):936-43. doi: 10.3201/eid2505.181823
- Singh B, Cocker D, Ryan H, et al. Linezolid for drug-resistant tuberculosis. Cochrane Database Syst Rev. 2017;2017(11):CD012836. doi: 10.1002/14651858.CD012836
- World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO/CDS/TB/2019.3. Geneva, World Health Organization, 2019.
- Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis. 2004;84(1-2):29-44. doi: 10.1016/j.tube.2003.08.003
- Levitte S, Adams KN, Berg RD, et al. Mycobacterial acid tolerance enables phagolysosomal survival and establishment of tuberculous infection in vivo. Cell Host Microbe. 2016;20(2):250-8. doi: 10.1016/j.chom.2016.07.007
- Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994;263(5147):678-81. doi: 10.1126/science.8303277
- van der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell. 2007;129(7):1287-98. doi: 10.1016/j.cell.2007.05.059
- Raghuvanshi S, Sharma P, Singh S, et al. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci. 2010;107(50):21653-8. doi: 10.1073/pnas.1007967107
- Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. New Engl J Med. 2001;344(17):1294-303. doi: 10.1056/NEJM200104263441706
- Fatima S, Kamble SS, Dwivedi VP, et al. Mycobacterium tuberculosis programs mesenchymal stem cells to establish dormancy and persistence. J Clin Invest. 2020;130(2):655-61. doi: 10.1172/JCI128043
- Das B, Kashino SS, Pulu I, et al. CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med. 2013;5(170):170. doi: 10.1126/scitranslmed.3004912
- Khan A, Mann L, Papanna R, et al. Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy. Sci Rep. 2017;7(1):1-15. doi: 10.1038/s41598-017-15290-z
- Tardif S, Ross C, Bergman P,et al. Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci. 2015;70(5):577-88. doi: 10.1093/gerona/glu101
- Gutierrez MG, Master SS, Singh SB, et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004;119(6):753-66. doi: 10.1016/j.cell.2004.11.038
- Parida SK, Madansein R, Singh N, et al. Cellular therapy in tuberculosis. Int J Infect Dis. 2015;32:32-8. doi: 10.1016/j.ijid.2015.01.016
- Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380. doi: 10.3201/eid1303.061400
- Wakamoto Y, Dhar N, Chait R, et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science. 2013;339(6115):91-5. doi: 10.1126/science.1229858
- Cohen KA, Abeel T, McGuire AM, et al. Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa. IntJMycobacteriol. 2015;4:24-5. doi: 10.1016/j.ijmyco.2014.11.028
- Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136(2):420-5. doi: 10.1378/chest.08-2427
- Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med. 2014;2(2):108-22. doi: 10.1016/S2213-2600(13)70234-0
- Matthay MA, Goolaerts A, Howard JP, et al. Mesenchymal Stem Cells for Acute Lung Injury: Preclinical Evidence. Crit Care Med. 2010;38(10):569-73. doi: 10.1097/CCM.0b013e3181f1ff1d
- Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007;4(9):e269. doi: 10.1371/journal.pmed.0040269
- Tropea KA, Leder E, Aslam M, et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2012;302(9):829-37. doi: 10.1152/ajplung.00347.2011
- Spees JL, Olson SD, Whitney MJ, et al. Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci. 2006;103(5):1283-8. doi: 10.1073/pnas.0510511103
- Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759-65. doi: 10.1038/nm.2736
- Sinclair K, Yerkovich ST, Chambers DC. Mesenchymal stem cells and the lung. Respirology. 2013;18(3):397-411. doi: 10.1111/resp.12050
- Ерохин В.В., Васильева И.А., Коноплянников А.Г., и др. Системная трансплантация аутологичных мезенхимальных стволовых клеток костного мозга в лечении больных множественным лекарственно-устойчивым туберкулезом легких. Туберкулез и болезни легких. 2008;85(10):3-6 [Erohin VV, Vasil'eva IA, Konoplyannikov AG, et al. Sistemnaia transplantatsiia autologichnykh mezenkhimal'nykh stvolovykh kletok kostnogo mozga v lechenii bol'nykh mnozhestvennym lekarstvenno-ustoichivym tuberkulezom legkikh. Tuberkulez i bolezni legkikh. 2008;85(10):3-6 (in Russian)].
- Danjuma L, Mok PL, Higuchi A, et al. Modulatory and regenerative potential of transplanted bone marrow-derived mesenchymal stem cells on rifampicin-induced kidney toxicity. Regen Ther. 2018;9:100-10. doi: 10.1016/j.reth.2018.09.001
- Yudintceva NM, Bogolyubova IO, Muraviov AN, et al. Application of the allogenic mesenchymal stem cells in the therapy of the bladder tuberculosis. J Tissue Eng Regen Med. 2018;12(3):1580-93. doi: 10.1002/term.2583
- Орлова Н.В., Муравьев А.Н., Блюм Н.М., и др. Экспериментальная реконструкция мочевого пузыря кролика с использованием аллогенных клеток различного тканевого происхождения. Медицинский альянс. 2016;1:50-2
- Гусейнова Ф.М., Виноградова Т.И., Заболотных Н.В., и др. Влияние клеточной терапии мезенхимными клетками стромы костного мозга на процессы репарации при экспериментальном туберкулезном сальпингите. Медицинский альянс. 2017;3:35-43.
- Ариэль Б.М., Гусейнова Ф.М., Виноградова Т.И., и др. Мезенхимные клетки стромы костного мозга при туберкулезе гениталий у кроликов (экспериментальное исследование с морфологическим контролем). Обзоры по клинической фармакологии и лекарственной терапии. 2017;15(2):47-55